Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System ((JJ-TRAILS))

22. juli 2019 opdateret af: Michael L. Dennis, Ph.D., Chestnut Health Systems

Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System: Multi-site Implementation Study

This is a multi site experiment to evaluate the impact of various strategies for increasing the use of evidence based screening, assessment and linkage to substance use treatment. All sites collect baseline data and receive a core intervention. Half are then randomly assigned to get an additional year of coaching to facilitate implementation.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

Background: The Juvenile Justice-Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS) study is a cooperative implementation science initiative involving the National Institute on Drug Abuse, six Research Centers, a Coordinating Center, and Juvenile Justice Partners representing seven U.S. states. The pooling of resources across Centers enables a robust implementation study design involving 36 juvenile justice agencies and their behavioral health partner agencies, coproducing a study protocol that has potential to advance implementation science, meets the needs of all constituencies (funding agency, researchers, partners, study sites), and can be implemented with fidelity across the cooperative can be challenging.

Methods/design: The JJ-TRIALS primary study uses a head-to-head cluster randomized trial with a phased rollout to evaluate the differential effectiveness of two conditions (Core and Enhanced) in 36 sites located in 7 states. Core strategies for promoting change are compared to an Enhanced strategy that incorporate all core strategies plus active facilitation. Target outcomes include improvements in evidence-based screening, assessment, and linkage to substance use treatment.

Primary Research Questions:

  1. Does the Core and/or Enhanced Intervention reduce unmet need by increasing Cascade retention related to screening, assessment, treatment initiation, engagement and continuing care?
  2. Does the addition of the Enhanced Intervention components further increase the percentage of youth retained in the Cascade relative to the Core components?
  3. Does the addition of the Enhanced Intervention components improve service quality relative to Core sites?
  4. Do staff perceptions of the value of best practices increase over time, and are increases more pronounced in Enhanced sites?

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

839

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Emory University
    • Illinois
      • Bloomington, Illinois, Forenede Stater, 61701
        • Chestnut Health Systems
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40508
        • University of Kentucky
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20892
        • National Institute on Drug Abuse
    • Mississippi
      • Starkville, Mississippi, Forenede Stater, 39759
        • Mississippi State University
    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19122
        • Temple University
    • Texas
      • Fort Worth, Texas, Forenede Stater, 76129
        • Texas Christian University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Specific site inclusion criteria include: (a) ability to provide youth service records, (b) service to youth under community supervision, (c) access to treatment provider(s) if treatment is not provided directly by the JJ agency, (d) participation in requisite intervention training/activities,(e) minimum average case flow of 10 youth per month, (f) minimum of 10 staff per site, and (g) a senior JJ staff member who agrees to serve as site leader/liaison during the study. Study sites are geographically dispersed and were identified by state JJ agencies (and not selected for particular substance use or related BH service needs).

Youth inclusion criteria include: all youth entering the juvenile justice system during the period within the exception of those who are already in treatment at the time that they are referred to the juvenile justice agency.

Staff inclusion criteria include: all staff actively working with the youth under community supervision in the site with exclusion only of higher level administrative or regional staff over multiple units..

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control
During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
Aktiv komparator: Core

In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.

these principles to their improvement efforts during the implementation phase.

Andre navne:
  • GAT, DDDM
Eksperimentel: Enhanced
While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
Andre navne:
  • GAT, DDDM
Andre navne:
  • DDDM, Facilitation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Service Cascade: % Referred to Substance Use Treatment
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth referred to substance use treatment divided by the number of youth identified as need of substance use treatment.
120 weeks
Staff Perception: Value of Evidenced Based Substance Use Treatment
Tidsramme: 120 weeks
Calculated from staff surveys at juvenile justice and substance use treatment agencies as the average staff ranking of the perceived "value" of using of evidence-based substance use treatment services.
120 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Service Cascade: % Screened for Substance Use Problems
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth "Screened" for substance use problems divided by the number of youth entering the juvenile justice system.
120 weeks
Service Cascade: % Clinically Assessed for Substance Use Problems
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth "Clinically Assessed" for substance use problems divided by the number of youth entering the juvenile justice system.
120 weeks
Service Cascade: % In Need of Substance Use Treatment
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth identified (via screening, clinical assessment or other sources) as "In Need of Substance Use Treatment" divided by the number of youth entering the juvenile justice system.
120 weeks
Service Cascade: % Initiating Substance Use Treatment
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth "Initiating" Substance Use Treatment within 90 days of referral" divided by the number referred to treatment from the juvenile justice system.
120 weeks
Service Cascade: % Engaged in Substance Use Treatment
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the number of youth "Engaged" in Substance Use Treatment for 6 weeks or more weeks divided by the number initiating treatment.
120 weeks
Service Cascade: % With Substance Use Treatment Continuing Care
Tidsramme: 120 weeks
number of youth "Continuing" to receive substance use treatment services forCalculated from juvenile justice and substance use treatment agency records as the 90 days or more divided by the number initiating treatment.
120 weeks
Service Quality: Timing of Screening or Clinical Assessment
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the mean days from entry into the justice system to the first of screening or clinical assessment for substance use problems.
120 weeks
Service Quality: Timing of Substance Use Treatment Initiation
Tidsramme: 120 weeks
Calculated from juvenile justice and substance use treatment agency records as the mean days from referral to and initiation of substance use treatment.
120 weeks
Service Quality: Number of Evidence Based Practices
Tidsramme: 120 Weeks
Based on agency surveys and youth records from juvenile justice and substance use treatment agencies, the number of steps using 1 or more evidenced based practices in each of the following steps along the service cascade: screening, clinical assessment, referral, substance use treatment.
120 Weeks
Staff Perception: Value of Evidenced Based Screening
Tidsramme: 120 weeks
Calculated from staff surveys at juvenile justice and substance use treatment agencies as the average staff ranking of the perceived "value" of using of evidence-based screening.
120 weeks
Staff Perception: Value of Evidenced Based Clinical Assessment
Tidsramme: 120 weeks
Calculated from staff surveys at juvenile justice and substance use treatment agencies as the average staff ranking of the perceived "value" of using of evidence-based clinical assessment.
120 weeks
Staff Perception: Value of Evidenced Based Substance Use Prevention
Tidsramme: 120 weeks
Calculated from staff surveys at juvenile justice and substance use treatment agencies as the average staff ranking of the perceived "value" of using of evidence-based substance use prevention.
120 weeks
Staff Perception: Value of Evidenced Based HIV Risk Prevention
Tidsramme: 120 weeks
Calculated from staff surveys at juvenile justice and substance use treatment agencies as the average staff ranking of the perceived "value" of using of evidence-based HIV Risk prevention.
120 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Christy K Scott, Ph.D., Chestnut Health Systems
  • Ledende efterforsker: Danica K Knight, Ph.D., Texas Christian University
  • Ledende efterforsker: Michael L Dennis, Ph.D., Chestnut Health Systems
  • Ledende efterforsker: Tisha R Wiley, Ph.D., National Institute on Drug Abuse (NIDA)
  • Ledende efterforsker: Gail A Wasserman, Ph.D., Columbia University
  • Ledende efterforsker: Ralph DiClemente, Ph.D., Emory University
  • Ledende efterforsker: Gene H Brody, Ph.D., Emory University
  • Ledende efterforsker: Angela A Robertson, Ph.D., Mississippi State University
  • Ledende efterforsker: Steven R Belenko, Ph.D., Temple University
  • Ledende efterforsker: Carl G Leukefeld, Ph.D., University of Kentucky

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2013

Primær færdiggørelse (Faktiske)

31. januar 2019

Studieafslutning (Faktiske)

30. juni 2019

Datoer for studieregistrering

Først indsendt

22. januar 2016

Først indsendt, der opfyldte QC-kriterier

29. januar 2016

Først opslået (Skøn)

3. februar 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. juli 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. juli 2019

Sidst verificeret

1. juli 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • JJ-TRIALS
  • U01DA036221 (U.S. NIH-bevilling/kontrakt)
  • U01DA036226 (U.S. NIH-bevilling/kontrakt)
  • U01DA036233 (U.S. NIH-bevilling/kontrakt)
  • U01DA036176 (U.S. NIH-bevilling/kontrakt)
  • U01DA036225 (U.S. NIH-bevilling/kontrakt)
  • U01DA036224 (U.S. NIH-bevilling/kontrakt)
  • U01DA036158 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The coordinating center is charged with creating de-identified versions of agency, staff and client level service data available at the end of the study.

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner